Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 53, 2023 - Issue 5
70
Views
0
CrossRef citations to date
0
Altmetric
Animal Pharmacokinetics and metabolism

Impact of tectoridin on the pharmacokinetics of florfenicol via targeting cytochrome P450 and P-glycoprotein of rats

, , , , &
Pages 429-437 | Received 03 Aug 2023, Accepted 16 Sep 2023, Published online: 02 Oct 2023

References

  • Bai J, Zhao S, Fan X, Chen Y, Zou X, Hu M, Wang B, Jin J, Wang X, Hu J, et al. 2019. Inhibitory effects of flavonoids on P-glycoprotein in vitro and in vivo: food/herb–drug interactions and structure–activity relationships. Toxicol Appl Pharmacol. 369:49–59. doi: 10.1016/j.taap.2019.02.010.
  • Cannon M, Harford S, Davies J. 1990. A comparative study on the inhibitory actions of chloramphenicol, thiamphenicol and some fluorinated derivatives. J Antimicrob Chemother. 26(3):307–317. doi: 10.1093/jac/26.3.307.
  • Committee for Medicinal Products for Human Use (CHMP). 2012. Guideline on bioanalytical method validation. London: European Medicines Agency (EMA).
  • Geng T, Si H, Kang D, Li Y, Huang W, Ding G, Wang Z, Bi Y, Zhang H, Xiao W. 2015. Influences of Re Du Ning injection, a traditional Chinese medicine injection, on the CYP450 activities in rats using a cocktail method. J Ethnopharmacol. 174:426–436. doi: 10.1016/j.jep.2015.08.035.
  • Guengerich FP, Turvy CG. 1991. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther. 256(3):1189–1194.
  • Guo M, Sun Y, Zhang Y, Bughio S, Dai X, Ren W, Wang L. 2014. E. coli infection modulates the pharmacokinetics of oral enrofloxacin by targeting P-glycoprotein in small intestine and CYP450 3A in liver and kidney of broilers. PLOS One. 9(1):e87781. doi: 10.1371/journal.pone.0087781.
  • Guo YJ, Liang DL, Xu ZS, Ye Q. 2014. In vivo inhibitory effects of puerarin on selected rat cytochrome P450 isoenzymes. Pharmazie. 69(5):367–370.
  • Ho SP, Hsu TY, Che MH, Wang WS. 2000. Antibacterial effect of chloramphenicol, thiamphenicol and florfenicol against aquatic animal bacteria. J Vet Med Sci. 62(5):479–485. doi: 10.1292/jvms.62.479.
  • Institute for Laboratory Animal Research. 1996. Guide for the care & use of laboratory animals. Washington (DC): National Research Council (US).
  • Kim SB, Yoon IS, Kim KS, Cho SJ, Kim YS, Cho HJ, Chung SJ, Chong S, Kim DD. 2014. In vitro and in vivo evaluation of the effect of puerarin on hepatic cytochrome p450-mediated drug metabolism. Planta Med. 80(7):561–567. doi: 10.1055/s-0034-1368350.
  • Kopečná-Zapletalová M, Krasulová K, Anzenbacher P, Hodek P, Anzenbacherová E. 2017. Interaction of isoflavonoids with human liver microsomal cytochromes P450: inhibition of CYP enzyme activities. Xenobiotica. 47(4):324–331. doi: 10.1080/00498254.2016.1195028.
  • Li S, Li X, Yuan D, Wang B, Yang R, Zhang M, Li J, Zeng F. 2021. Effects of paeoniflorin on the activities and mRNA expression of rat CYP1A2, CYP2C11 and CYP3A1 enzymes in vivo. Xenobiotica. 51(9):961–967. doi: 10.1080/00498254.2017.1404659.
  • Li SC, Zhang M, Wang B, Li XT, Liang G. 2023. Coptisine modulates the pharmacokinetics of florfenicol by targeting CYP1A2, CYP2C11 and CYP3A1 in the liver and P-gp in the jejunum of rats: a pilot study. Xenobiotica. 53(3):207–214. doi: 10.1080/00498254.2023.2211135.
  • Liu N, Guo M, Mo F, Sun YH, Yuan Z, Cao LH, Jiang SX. 2012. Involvement of P-glycoprotein and cytochrome P450 3A in the metabolism of florfenicol of rabbits. J Vet Pharmacol Ther. 35(2):202–205. doi: 10.1111/j.1365-2885.2011.01310.x.
  • Liu N. 2011. The metabolism mechanism of florfenicol and drug–drug interaction in rabbits [dissertation]. Nanjing: Nanjing Agricultural University (in Chinese).
  • Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(–Delta Delta C(T)) method. Methods. 25(4):402–408. doi: 10.1006/meth.2001.1262.
  • Lo A, Burckart GJ. 1999. P-glycoprotein and drug therapy in organ transplantation. J Clin Pharmacol. 39(10):995–1005. doi: 10.1177/00912709922011755.
  • Martignoni M, Groothuis GM, de Kanter R. 2006. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol. 2(6):875–894. doi: 10.1517/17425255.2.6.875.
  • Paape MJ, Miller RH, Ziv G. 1990. Effects of florfenicol, chloramphenicol, and thiamphenicol on phagocytosis, chemiluminescence, and morphology of bovine polymorphonuclear neutrophil leukocytes. J Dairy Sci. 73(7):1734–1744. doi: 10.3168/jds.S0022-0302(90)78850-9.
  • Pérez R, Palma C, Drápela C, Sepulveda M, Espinoza A, Peñailillo AK. 2015. Pharmacokinetics of florfenicol after intravenous administration in Escherichia coli lipopolysaccharide-induced endotoxaemic sheep. J Vet Pharmacol Ther. 38(2):144–149. doi: 10.1111/jvp.12160.
  • Ramakrishna R, Bhateria M, Singh R, Bhatta RS. 2016. Evaluation of the impact of 16-dehydropregnenolone on the activity and expression of rat hepatic cytochrome P450 enzymes. J Steroid Biochem Mol Biol. 163:183–192. doi: 10.1016/j.jsbmb.2016.05.018.
  • Semeniuk M, Ceré LI, Ciriaci N, Bucci-Muñoz M, Villanueva SSM, Mottino AD, Catania VA, Rigalli JP, Ruiz ML. 2020. Regulation of hepatic P-gp expression and activity by genistein in rats. Arch Toxicol. 94(5):1625–1635. doi: 10.1007/s00204-020-02708-3.
  • Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 270(1):414–423.
  • Sidhu P, Rassouli A, Illambas J, Potter T, Pelligand L, Rycroft A, Lees P. 2014. Pharmacokinetic–pharmacodynamic integration and modelling of florfenicol in calves. J Vet Pharmacol Ther. 37(3):231–242. doi: 10.1111/jvp.12093.
  • Tousen Y, Takebayashi J, Kondo T, Fuchino H, Kawano N, Inui T, Yoshimatsu K, Kawahara N, Ishimi Y. 2019. Safety and efficacy assessment of isoflavones from Pueraria (kudzu) flower extract in ovariectomised mice: a comparison with soy isoflavones. Int J Mol Sci. 20(12):2867. doi: 10.3390/ijms20122867.
  • Wang GY, Tu P, Chen X, Guo YG, Jiang SX. 2013. Effect of three polyether ionophores on pharmacokinetics of florfenicol in male broilers. J Vet Pharmacol Ther. 36(5):494–501. doi: 10.1111/jvp.12020.
  • Wang GY, Zheng HH, Zhang KY, Yang F, Kong T, Zhou B, Jiang SX. 2018. The roles of cytochrome P450 and P-glycoprotein in the pharmacokinetics of florfenicol in chickens. Iran J Vet Res. 19(1):9–14.
  • Wang J, Tang Y, Lv X, Zhang J, Ma B, Wen X, Bao Y, Wang G. 2020. Tectoridin inhibits osteoclastogenesis and bone loss in a murine model of ovariectomy-induced osteoporosis. Exp Gerontol. 140:111057. doi: 10.1016/j.exger.2020.111057.
  • Xiao CQ, Chen R, Lin J, Wang G, Chen Y, Tan ZR, Zhou HH. 2012. Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants. Xenobiotica. 42(2):173–178. doi: 10.3109/00498254.2011.615954.
  • Xiong Y, Yang Y, Yang J, Chai H, Li Y, Yang J, Jia Z, Wang Z. 2010. Tectoridin, an isoflavone glycoside from the flower of Pueraria lobata, prevents acute ethanol-induced liver steatosis in mice. Toxicology. 276(1):64–72. doi: 10.1016/j.tox.2010.07.007.
  • Xu RA, Xu ZS, Ge RS. 2014. Effects of hydroxysafflor yellow A on the activity and mRNA expression of four CYP isozymes in rats. J Ethnopharmacol. 151(3):1141–1146. doi: 10.1016/j.jep.2013.12.025.
  • Zhang L, Wei K, Xu J, Yang D, Zhang C, Wang Z, Li M. 2016. Belamcanda chinensis (L.) DC—an ethnopharmacological, phytochemical and pharmacological review. J Ethnopharmacol. 186:1–13. doi: 10.1016/j.jep.2016.03.046.
  • Zheng J, Chen B, Jiang B, Zeng L, Tang ZR, Fan L, Zhou HH. 2010. The effects of puerarin on CYP2D6 and CYP1A2 activities in vivo. Arch Pharm Res. 33(2):243–246. doi: 10.1007/s12272-010-0209-2.
  • Zhou SF, Liu JP, Chowbay B. 2009. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 41(2):89–295. doi: 10.1080/03602530902843483.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.